DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

$ API Reference Price

$ API Reference Price

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 432

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 68497-62-1, Pramiracetam [inn], N-[2-[di(propan-2-yl)amino]ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide, N-(2-(diisopropylamino)ethyl)-2-(2-oxopyrrolidin-1-yl)acetamide, 1-pyrrolidineacetamide, n-(2-(bis(1-methylethyl)amino)ethyl)-2-oxo-, 4449f8i3le

Molecular Formula

C₁₄H₂₇N₃O₂

Molecular Weight

269.38 g/mol

InChI Key

ZULJGOSFKWFVRX-UHFFFAOYSA-N

FDA UNII

4449F8I3LE

Pramiracetam has been previously approved in some eastern European countries under the brand names Pramistar, Neupramir, and Remen. It was also previously approved in the United States with orphan drug designation. Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive functioning post-electroconvulsive therapy in severe depression.

1 2D Structure

Pramiracetam

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[2-[di(propan-2-yl)amino]ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide

2.1.2 InChI

InChI=1S/C14H27N3O2/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19/h11-12H,5-10H2,1-4H3,(H,15,18)

2.1.3 InChI Key

ZULJGOSFKWFVRX-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C

2.2 Other Identifiers

2.2.1 UNII

4449F8I3LE

2.3 Synonyms

2.3.1 MeSH Synonyms

1. N-(2-(bis(1-methylethyl)amino)ethyl)-2-oxo-1-pyrrolidineacetamide

2. Pramiracetam Hydrochloride

3. Pramiracetam Sulfate

4. Pramistar

2.3.2 Depositor-Supplied Synonyms

1. 68497-62-1

2. Pramiracetam [inn]

3. N-[2-[di(propan-2-yl)amino]ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide

4. N-(2-(diisopropylamino)ethyl)-2-(2-oxopyrrolidin-1-yl)acetamide

5. 1-pyrrolidineacetamide, N-(2-(bis(1-methylethyl)amino)ethyl)-2-oxo-

6. 4449f8i3le

7. Pramiracetam (inn)

8. N-[2-[bis(1-methylethyl)amino]ethyl]-2-oxo-1-pyrrolidineacetamide

9. 1-pyrrolidineacetamide, N-[2-[bis(1-methylethyl)amino]ethyl]-2-oxo-

10. Pramiracetamum

11. Pramiracetamum [inn-latin]

12. Unii-4449f8i3le

13. N-(2-(bis(1-methylethyl)amino)ethyl)-2-oxo-1-pyrrolidineacetamide

14. Pramiracetam/ci-879

15. Pramiracetam [mi]

16. Ci-879 Free Base

17. Mls006010035

18. Pramiracetam [who-dd]

19. Schembl195465

20. Benzoic Acid, O-(p-toluyl)-

21. Chembl159776

22. Dtxsid60218604

23. Chebi:135110

24. Hms3656m20

25. Hms3884n10

26. Bcp27900

27. Zinc1856108

28. S2594

29. Akos005066359

30. Ac-8798

31. Ccg-267142

32. Cs-1573

33. Db13247

34. Hs-0092

35. Ncgc00346668-01

36. Ncgc00346668-04

37. Hy-17455

38. Smr004701212

39. Db-055157

40. Ft-0630777

41. P2061

42. Sw219170-1

43. C76170

44. D08405

45. Ab01566859_01

46. 497p621

47. A836161

48. Q415746

49. Q-201610

50. Z221101674

51. N-(2-(diisopropylamino)ethyl)-2-oxo-1-pyrrolidineacetamide

52. Amacetam, N-[2-(diisopropylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide

53. N-[2-[di(propan-2-yl)amino]ethyl]-2-(2-oxo-1-pyrrolidinyl)acetamide

54. N-{2-[bis(propan-2-yl)amino]ethyl}-2-(2-oxopyrrolidin-1-yl)acetamide

55. N-[2-[bis(1-methylethyl)amino]ethyl]-2-oxo-1-pyrrolidineacetamide, Vinpotropil

56. N-[2-[di(propan-2-yl)amino]ethyl]-2-(2-oxidanylidenepyrrolidin-1-yl)ethanamide

2.4 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₁₄H₂₇N₃O₂
Molecular Weight	269.38 g/mol
XLogP3	0.8
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	7
Exact Mass	269.21032711 g/mol
Monoisotopic Mass	269.21032711 g/mol
Topological Polar Surface Area	52.6 Å²
Heavy Atom Count	19
Formal Charge	0
Complexity	308
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 ATC Code

N - Nervous system

N06 - Psychoanaleptics

N06B - Psychostimulants, agents used for adhd and nootropics

N06BX - Other psychostimulants and nootropics

N06BX16 - Pramiracetam

ABOUT THIS PAGE

Find Pramiracetam manufacturers, exporters & distributors on PharmaCompass

Pramiracetam

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

$ API Reference Price

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 432

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?